.png){kind=icon}
返回
Screening for prostate cancer
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(03)12890-5.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Epidemiologically, screening is,justified by the importance of the disease and the lack of prospects for primary prevention, but evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. The available screening tests do not always detect men whose lesions could result in future morbidity or mortality. Evidence is limited for the benefits of treatment for localised cancers detected through screening, whereas the evidence for harm is clear. Observational evidence for the effect of population screening programmes is mixed, with no clear association between intensity of screening and reduced prostate cancer mortality. Screening for prostate cancer cannot be justified in low-risk populations, but the balance of benefit and harm will be more favourable after risk stratification. Prostate cancer screening can be justified only in research programmes designed to assess its effectiveness and help identify the groups who may benefit.
Keyword:
RANDOMIZED CONTROLLED TRIAL
RADICAL PROSTATECTOMY
SURVEILLANCE SERIES
INTERPRETING TRENDS
INTERNATIONAL TRENDS
PREVENTION TRIAL
MORTALITY
MEN
ANTIGEN
DEATH
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
暂无机构信息
引用论文
.png){kind=icon}
European randomized study of prostate cancer screening:: first-year results of the Finnish trial
OAAI
OAAI分享收藏A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancerOAAI
OAAI分享收藏
查看更多内容